| Title | Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. |
| Author(s) | Hasebe N, Kikuchi K, NICE Combi Study Group |
| Institution | First Department of Internal Medicine, Asahikawa Medical College, Asahikawa, Japan. haselove@asahikawa-med.ac.jp |
| Source | J Hypertens 2005 Feb; 23(2):445-53. |
| MeSH | Adolescent
Adult
Aged
Aged, 80 and over
Albuminuria
Antihypertensive Agents
Benzimidazoles
Biphenyl Compounds
Blood Pressure
Comparative Study
Creatinine
Delayed-Action Preparations
Double-Blind Method
Drug Therapy, Combination
Female
Heart Rate
Humans
Hypertension
Male
Middle Aged
Nifedipine
Research Support, Non-U.S. Gov't
Tetrazoles
Vasodilator Agents
|
| Abstract | OBJECTIVE: To compare the clinical efficacy of low-dose controlled-release (CR) nifedipine (20 mg/day) plus candesartan (8 mg/day) combination therapy with that of up-titrated candesartan (12 mg/day) monotherapy.
DESIGN: Randomized, double-blind study.
SETTING: Outpatient study. PATIENTS AND
PARTICIPANTS: Patients with essential hypertension, who did not achieve their target blood pressure with baseline treatment of candesartan 8 mg/day for 8 weeks.
MAIN OUTCOME MEASURES: Blood pressure, pulse pressure, urinary microalbumin excretion.
RESULTS: Blood pressure was significantly reduced in both groups (P < 0.05), but the reduction was significantly greater in the combination therapy group (12.1 +/- 1.4/8.7 +/- 0.9 mmHg) than in the up-titrated monotherapy group (4.1 +/- 1.4/4.6 +/- 0.9 mmHg) (P < 0.0001). The reduction in pulse pressure was significantly greater in the combination therapy group (3.3 +/- 1.2 mmHg) than in the up-titrated monotherapy group (0.7 +/- 1.2 mmHg) (P = 0.0031). Urinary microalbumin excretion decreased significantly in the combination therapy group (from 61.9 to 40.5 mg/g creatinine; P < 0.05), but not in the up-titrated monotherapy group.
CONCLUSIONS: These findings suggest that the low-dose combination therapy of nifedipine CR and candesartan is superior to the up-titrated monotherapy of candesartan in terms of blood pressure control and renal protection in patients with essential hypertension. |
| Language | eng |
| Pub Type(s) | Clinical Trial
Journal Article
Randomized Controlled Trial
|
| PubMed ID | 15662234 |
